I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
It is employed as Na+ channel blocker, local anesthetic and cAMP production inhibitor. It acts as a surfactant molecule possessing both hydrophilic and lipophilic properties, adrenergic antagonist, EC 220.127.116.11 (cholinesterase) inhibitor and EC 18.104.22.168 (Ca(2+)-transporting ATPase) inhibitor.
Viscusi ER, et al. The safety of liposome bupivacaine, a novel local analgesic formulation.Clinical pharmacology and therapeutics.,2014,30(2), 102-110.
Hu D, et al. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site.Clinical drug investigation.,2013,33(2), 109-115.
Hazard Statements: H300-H310-H330
Fatal if swallowed. Fatal in contact with skin. Fatal if inhaled.
Precautionary Statements: P301+P310a-P304+P340-P320-P330-P405-P501a
IF SWALLOWED: Immediately call a POISON CENTER/doctor IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Specific treatment is urgent (see label). Rinse mouth. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.